{"href":"https://api.simplecast.com/oembed?url=https%3A%2F%2Foncologypodcast.simplecast.com%2Fepisodes%2Fmetex14-nsclc-faq-part-1-_2UPzugc","width":444,"version":"1.0","type":"rich","title":"MET Exon 14 Mutation–Positive NSCLC: FAQ Part 1","thumbnail_width":300,"thumbnail_url":"https://image.simplecastcdn.com/images/165defb8-f7d7-44fe-a7eb-a59f2c35d334/1e4a0733-b759-40be-977b-dc1d138bcb0d/asco-metex14-podcasticon.jpg","thumbnail_height":300,"provider_url":"https://simplecast.com","provider_name":"Simplecast","html":"<iframe src=\"https://player.simplecast.com/e78211c8-cad4-413f-a166-e8f694b1a83d\" height=\"200\" width=\"100%\" title=\"MET Exon 14 Mutation–Positive NSCLC: FAQ Part 1\" frameborder=\"0\" scrolling=\"no\"></iframe>","height":200,"description":"Hear from international lung cancer experts Luis Paz-Ares, MD, PhD; D. Ross Camidge, MD, PhD; and Karen L. Reckamp, MD, MS, as they answer audience questions from a live CCO Webinar on METex14 mutation–positive NSCLC, from incorporation of testing for MET exon 14 alterations into standard of care to optimal use of MET-targeted therapies in this setting."}